Innovative Biopharmaceuticals from Oral Science
At Oragenics, we are focused on developing effective treatments for oral mucositis and becoming a leader in developing novel antibiotics against infectious diseases.
Learn More About OragenicsOragenics Acquires Noachis Terra, Inc.
NIH-created SARS-CoV-2 (COVID-19) Spike Protein Vaccine Technology could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”).
Learn More about Noachis TerraLearn More about the Acquisition of Noachis Terra
Exclusive Collaboration with Precigen
Our exclusive channel collaboration arrangement with Precigen contemplates the use of Precigen’s advanced transgene and cell engineering platforms for the development and production of revolutionary lantibiotics and live biotherapeutic products (LBP).
Learn More About Our CollaborationsFighting Global Bacterial Antibiotic Resistance
Oragenics, in collaboration with Precigen, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.
Learn More About LantibioticsAdjunctive Therapy for Oral Mucositis
Oragenics, in collaboration with Precigen, is also in the process of developing live biotherapeutic products (LBP) to treat oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus.
Learn More About LBP
